对比增强乳腺X线摄影中不对称背景实质强化:相关因素、诊断检查和临床结局
回顾性分析2012年12月至2023年7月连续对比增强乳腺X线摄影检查,175/12,856(1.4%)报告不对称背景实质强化,最常见相关因素为对侧放疗(n=94);初始诊断检查常包括靶向超声(n=107),即时MRI(n=65)和/或6个月随访CEM(n=69)使多数病例降级,BPE分级较初始CEM显著降低(两者p<0.01);随访中在可疑不对称BPE区域诊断出2例潜在癌症。
要点
- 不对称BPE报告率低(1.4%),多为良性且可找到明确病因(如对侧放疗、近期同侧乳腺治疗、单侧哺乳)。
- 即时MRI和6个月随访CEM可使多数病例BPE分级降级,两者较初始CEM的BPE分级均显著降低(p<0.01)。
- 罕见情况下不对称BPE可掩盖表现为非肿块强化的潜在恶性肿瘤,需额外仔细审视。
核心结论
- 表观不对称BPE多为良性发现且有可识别病因,但罕见情况下可能掩盖表现为非肿块强化的潜在恶性肿瘤,因此需要额外仔细审视。
研究设计与样本
- 回顾性审查2012年12月至2023年7月连续对比增强乳腺X线摄影检查,共识别175/12,856(1.4%)报告不对称BPE的检查(140例女性患者,平均年龄46±8.0岁)。
关键影像表现/征象
- 不对称BPE的报告确定性多为高(n=86),其次为中等(n=59)和低(n=30)。
- 相关因素包括对侧放疗(n=94)、近期同侧乳腺治疗(n=14)和单侧哺乳(n=4)。
- BI-RADS评分为0(n=21)、1/2(n=75)、3(n=67)、4(n=3)、6(n=1),或因不对称BPE以外的发现而给定(n=8)。
- 随访中在可疑不对称BPE区域诊断出2例潜在癌症,表现为非肿块强化。
诊断标准与关键数值
- 即时MRI(n=65)和/或6个月CEM随访(n=69)使多数病例降级,BPE分级较初始CEM显著降低(两者p<0.01)。
- 初始诊断检查常包括靶向超声(n=107)。
临床应用与阅片要点
- 靶向超声和MRI可用于评估无法解释的不对称背景实质强化。
- 不对称BPE的诊断检查在检查指标上差异很大,凸显该影像发现的临床挑战。
- 需要进一步研究以验证这些初步观察并建立标准化管理指南。
局限性
- 原文指出需要进一步研究以验证这些初步观察并建立标准化管理指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To summarize our institutional experience with contrast-enhanced mammography (CEM) exams reporting asymmetric background parenchymal enhancement (BPE).
MATERIALS AND METHODS: Consecutive CEMs performed between December 2012 and July 2023 were retrospectively reviewed to identify exams reporting asymmetric BPE. Associated factors, the level of reporting certainty, BI-RADS score, diagnostic workup, and clinical outcome were summarized. BPE grades and BI-RADS were compared between initial CEM vs. immediate MRI and 6-month follow-up CEM, when indicated, using the Sign test.
RESULTS: Overall, 175/12,856 (1.4%) CEMs (140 female patients, mean age, 46 ± 8.0 years) reported asymmetric BPE. Reporting certainty was mostly high (n = 86), then moderate (n = 59) and low (n = 30). Associated factors included contralateral irradiation (n = 94), recent ipsilateral breast treatment (n = 14), and unilateral breastfeeding (n = 4). BI-RADS scores were 0 (n = 21), 1/2 (n = 75), 3 (n = 67), 4 (n = 3), and 6 (n = 1), or given for a finding other than asymmetric BPE (n = 8). Initial diagnostic-workup often included targeted-US (n = 107). Immediate MRI (n = 65) and/or 6-month CEM follow-up (n = 69) downgraded most cases, with a significant decrease in BPE grade compared to the initial CEM (p < 0.01 for both). On follow-up, two underlying cancers were diagnosed in the area of questionable asymmetric BPE.
CONCLUSION: Apparent asymmetric BPE is most often a benign finding with an identifiable etiology. However, rarely, it may mask an underlying malignancy presenting as non-mass enhancement, thus requiring additional scrutiny.
CLINICAL RELEVANCE STATEMENT: The variability in the diagnostic-workup of apparent asymmetric background parenchymal enhancement stresses the clinical challenge of this radiological finding. Further studies are required to verify these initial observations and to establish standardized management guidelines.
KEY POINTS: Apparent asymmetric background parenchymal enhancement usually represents a benign clinical correlate, though rarely it may represent malignancy. Evaluation of asymmetric background parenchymal enhancement varied considerably in the metrics that were examined. Targeted US and MRI can be useful in evaluating unexplained asymmetric background parenchymal enhancement.
引用
- Nissan N, Gluskin J, Ochoa-Albiztegui RE, et al. Asymmetric background parenchymal enhancement on contrast-enhanced mammography: associated factors, diagnostic workup, and clinical outcome. Eur Radiol. 2024. PMID: 39080066. doi:10.1007/s00330-024-10856-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。